Latest News Archive
Please select Category, Year, and then Month to display items
20 December 2021
|
Story Igno van Niekerk
|
Photo Igno van Niekerk
![]()
Dr Samantha Potgieter, Senior Lecturer in the Department of Internal Medicine and Dr Nicholas Pearce, Senior Lecturer in the Department of Surgery comment on their team members’ commitment and determination during the pandemic.
On the forefront of the battle against the COVID-19 pandemic, two UFS doctors are leading a team of inspired healthcare workers in a superhuman effort to make a positive difference.
With the pandemic in its second year and the recurring challenges of new waves and strains consistently in the news, one would expect the doctors to be tired. However, quite the opposite is true. Upon entering the office where Dr Samantha Potgieter, Senior Lecturer in the Department of Internal Medicine and Dr Nicholas Pearce, Senior Lecturer in the Department of Surgery are in a meeting with colleagues, the debate is vibrant; an energetic sense of mission.
Miraculously succeeded
My brief is to collect stories and experiences they’ve had over the past 18 months at the Tumelo ward for general and high-care patients, where the team has miraculously succeeded in not running out of oxygen or ventilators, despite handling high volumes of patients from the Free State and Northern Cape. “We saw those pictures of piled-up bodies in Italy. We were committed to avoiding that at all costs. And we did.”
Success stories? First mentioned are their team members’ commitment and determination. The team had to stand in when families could not support dying patients. “They did not die alone. Our team was there.”
“Really sad and frustrating are the deaths that could have been prevented. Unvaccinated patients. They arrive ill, wanting to know if they can get it. Too late...” – Dr Nicholas Pearce
Then came hope
Sad stories? The past year has had its share of sad stories. “Someone comes in during the morning, needs oxygen, in the afternoon they are in ICU, then ventilator – and then they die. We’ve never faced anything like this before.”
Then came hope. Vaccines. Dr Pearce is in charge of the vaccination site at Universitas Hospital. “Really sad and frustrating are the deaths that could have been prevented. Unvaccinated patients. They arrive ill, wanting to know if they can get it. Too late ...” He opens his cell phone – shares the stats. “We can handle 2 000 vaccinations a day. At the moment about 250 comes in.” He shakes his head.
“We can beat this virus, but we need to stand together ...”
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004